{"success":true,"data":{"pressRelease":{"id":"4658","rtpr_id":"nPn91mmZ4a","ticker":"AQST","exchange":"NASDAQ","all_tickers":["AQST"],"title":"AQST DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026","author":"PR Newswire","published_at":"2026-04-22T12:26:00.064Z","article_body":"AQST DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026\n\nPR Newswire\n\nNEW YORK, April 22, 2026\n\nFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669670-1&h=4041531708&u=https%3A%2F%2Fwww.faruqilaw.com%2Fattorney%2F22%2Fjames-m-wilson-jr&a=James+(Josh)+Wilson)\nEncourages Investors Who Suffered Losses In Aquestive To Contact Him Directly\nTo Discuss Their Options\n\nIf you purchased or acquired securities in Aquestive\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669670-1&h=4110405733&u=https%3A%2F%2Fwww.faruqilaw.com%2FAQST&a=Aquestive)\nbetween June 16, 2025 and January 8, 2026 and would like to discuss your legal\nrights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292\nor 212-983-9330 (Ext. 1310).\n\n[You may also click here for additional information]\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669670-1&h=2757782051&u=https%3A%2F%2Fwww.faruqilaw.com%2FAQST&a=%5BYou+may+also+click+here+for+additional+information%5D)\n\nNEW YORK, April 22, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669670-1&h=535095726&u=https%3A%2F%2Fwww.faruqilaw.com%2F&a=Faruqi+%26+Faruqi%2C+LLP)\n, a leading national securities law firm, is investigating potential claims\nagainst Aquestive Therapeutics, Inc. (\"Aquestive\" or the \"Company\") (NASDAQ:\nAQST) and reminds investors of the May 4, 2026 deadline to seek the role of\nlead plaintiff in a federal securities class action that has been filed\nagainst the Company.\n\n(https://mma.prnewswire.com/media/2457438/Faruqi_Logo.html)\n\nFaruqi & Faruqi is a leading national securities law firm with offices in\nNew York, Pennsylvania, California and Georgia. The firm has recovered\nhundreds of millions of dollars for investors since its founding in 1995. See\nwww.faruqilaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669670-1&h=24004518&u=https%3A%2F%2Fwww.faruqilaw.com%2F&a=www.faruqilaw.com)\n.\n\nAs detailed below, the complaint alleges that the Company and its executives\nviolated federal securities laws by making false and/or misleading statements\nand/or failing to disclose that: the true state of Aquestive's NDA for\nAnaphylm; pertinently, Aquestive concealed or otherwise minimized the\nsignificance of the human factors involved in the use and deployment of its\nsublingual film, such as packaging, use, administration, and labeling.\n\nOn January 9, 2026, Aquestive's President and Chief Executive Officer\nannounced that \"[a]s part of its ongoing review of the Company's NDA for\nAnaphylm, the FDA notified us that it had identified deficiencies in the NDA\nthat preclude discussion of labeling and post-marketing commitments at this\ntime,\" stating that \"the notification did not specify the deficiencies[.]\"\n\nOn this news, Aquestive's stock price fell $2.30 per share, or 37.04%, to\nclose at $3.91 per share on January 9, 2026.\n\nThe court-appointed lead plaintiff is the investor with the largest financial\ninterest in the relief sought by the class who is adequate and typical of\nclass members who directs and oversees the litigation on behalf of the\nputative class. Any member of the putative class may move the Court to serve\nas lead plaintiff through counsel of their choice, or may choose to do nothing\nand remain an absent class member. Your ability to share in any recovery is\nnot affected by the decision to serve as a lead plaintiff or not.\n\nFaruqi & Faruqi, LLP also encourages anyone with information regarding\nAquestive's conduct to contact the firm, including whistleblowers, former\nemployees, shareholders and others.\n\nTo learn more about the Aquestive Therapeutics class action, go to\nwww.faruqilaw.com/AQST\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669670-1&h=3173999994&u=https%3A%2F%2Fwww.faruqilaw.com%2FAQST&a=www.faruqilaw.com%2FAQST)\nor call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or\n212-983-9330 (Ext. 1310).\n\nFollow us for updates on LinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669670-1&h=176248765&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Ffaruqi-%26-faruqi-llp%2F&a=LinkedIn)\n, on X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669670-1&h=1926169229&u=https%3A%2F%2Fx.com%2Ffaruqilaw&a=X)\n, or on Facebook\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669670-1&h=3236282064&u=https%3A%2F%2Fwww.facebook.com%2FFaruqiLaw%2F&a=Facebook)\n.\n\nAttorney Advertising. The law firm responsible for this advertisement is\nFaruqi & Faruqi, LLP (www.faruqilaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669670-1&h=3401306933&u=http%3A%2F%2Fwww.faruqilaw.com%2F&a=www.faruqilaw.com)\n). Prior results do not guarantee or predict a similar outcome with respect to\nany future matter. We welcome the opportunity to discuss your particular case.\nAll communications will be treated in a confidential manner.\n\n(https://mma.prnewswire.com/media/2745617/Faruqi__Faruqi_LLP_James_Josh_Wilson.html)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/aqst-deadline-alert-faruqi--faruqi-llp-reminds-aquestive-therapeutics-aqst-investors-of-securities-class-action-deadline-on-may-4-2026-302749749.html\n(https://www.prnewswire.com/news-releases/aqst-deadline-alert-faruqi--faruqi-llp-reminds-aquestive-therapeutics-aqst-investors-of-securities-class-action-deadline-on-may-4-2026-302749749.html)\n\nSOURCE Faruqi & Faruqi, LLP\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2457438/Faruqi_Logo.jpg\nhttps://mma.prnewswire.com/media/2745617/Faruqi__Faruqi_LLP_James_Josh_Wilson.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn91mmZ4a","title":"AQST DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026","author":"PR Newswire","ticker":"AQST","created":"2026-04-22T12:26:00.064Z","tickers":["AQST"],"exchange":"NASDAQ","article_body":"AQST DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026\n\nPR Newswire\n\nNEW YORK, April 22, 2026\n\nFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669670-1&h=4041531708&u=https%3A%2F%2Fwww.faruqilaw.com%2Fattorney%2F22%2Fjames-m-wilson-jr&a=James+(Josh)+Wilson)\nEncourages Investors Who Suffered Losses In Aquestive To Contact Him Directly\nTo Discuss Their Options\n\nIf you purchased or acquired securities in Aquestive\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669670-1&h=4110405733&u=https%3A%2F%2Fwww.faruqilaw.com%2FAQST&a=Aquestive)\nbetween June 16, 2025 and January 8, 2026 and would like to discuss your legal\nrights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292\nor 212-983-9330 (Ext. 1310).\n\n[You may also click here for additional information]\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669670-1&h=2757782051&u=https%3A%2F%2Fwww.faruqilaw.com%2FAQST&a=%5BYou+may+also+click+here+for+additional+information%5D)\n\nNEW YORK, April 22, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669670-1&h=535095726&u=https%3A%2F%2Fwww.faruqilaw.com%2F&a=Faruqi+%26+Faruqi%2C+LLP)\n, a leading national securities law firm, is investigating potential claims\nagainst Aquestive Therapeutics, Inc. (\"Aquestive\" or the \"Company\") (NASDAQ:\nAQST) and reminds investors of the May 4, 2026 deadline to seek the role of\nlead plaintiff in a federal securities class action that has been filed\nagainst the Company.\n\n(https://mma.prnewswire.com/media/2457438/Faruqi_Logo.html)\n\nFaruqi & Faruqi is a leading national securities law firm with offices in\nNew York, Pennsylvania, California and Georgia. The firm has recovered\nhundreds of millions of dollars for investors since its founding in 1995. See\nwww.faruqilaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669670-1&h=24004518&u=https%3A%2F%2Fwww.faruqilaw.com%2F&a=www.faruqilaw.com)\n.\n\nAs detailed below, the complaint alleges that the Company and its executives\nviolated federal securities laws by making false and/or misleading statements\nand/or failing to disclose that: the true state of Aquestive's NDA for\nAnaphylm; pertinently, Aquestive concealed or otherwise minimized the\nsignificance of the human factors involved in the use and deployment of its\nsublingual film, such as packaging, use, administration, and labeling.\n\nOn January 9, 2026, Aquestive's President and Chief Executive Officer\nannounced that \"[a]s part of its ongoing review of the Company's NDA for\nAnaphylm, the FDA notified us that it had identified deficiencies in the NDA\nthat preclude discussion of labeling and post-marketing commitments at this\ntime,\" stating that \"the notification did not specify the deficiencies[.]\"\n\nOn this news, Aquestive's stock price fell $2.30 per share, or 37.04%, to\nclose at $3.91 per share on January 9, 2026.\n\nThe court-appointed lead plaintiff is the investor with the largest financial\ninterest in the relief sought by the class who is adequate and typical of\nclass members who directs and oversees the litigation on behalf of the\nputative class. Any member of the putative class may move the Court to serve\nas lead plaintiff through counsel of their choice, or may choose to do nothing\nand remain an absent class member. Your ability to share in any recovery is\nnot affected by the decision to serve as a lead plaintiff or not.\n\nFaruqi & Faruqi, LLP also encourages anyone with information regarding\nAquestive's conduct to contact the firm, including whistleblowers, former\nemployees, shareholders and others.\n\nTo learn more about the Aquestive Therapeutics class action, go to\nwww.faruqilaw.com/AQST\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669670-1&h=3173999994&u=https%3A%2F%2Fwww.faruqilaw.com%2FAQST&a=www.faruqilaw.com%2FAQST)\nor call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or\n212-983-9330 (Ext. 1310).\n\nFollow us for updates on LinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669670-1&h=176248765&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Ffaruqi-%26-faruqi-llp%2F&a=LinkedIn)\n, on X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669670-1&h=1926169229&u=https%3A%2F%2Fx.com%2Ffaruqilaw&a=X)\n, or on Facebook\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669670-1&h=3236282064&u=https%3A%2F%2Fwww.facebook.com%2FFaruqiLaw%2F&a=Facebook)\n.\n\nAttorney Advertising. The law firm responsible for this advertisement is\nFaruqi & Faruqi, LLP (www.faruqilaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4669670-1&h=3401306933&u=http%3A%2F%2Fwww.faruqilaw.com%2F&a=www.faruqilaw.com)\n). Prior results do not guarantee or predict a similar outcome with respect to\nany future matter. We welcome the opportunity to discuss your particular case.\nAll communications will be treated in a confidential manner.\n\n(https://mma.prnewswire.com/media/2745617/Faruqi__Faruqi_LLP_James_Josh_Wilson.html)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/aqst-deadline-alert-faruqi--faruqi-llp-reminds-aquestive-therapeutics-aqst-investors-of-securities-class-action-deadline-on-may-4-2026-302749749.html\n(https://www.prnewswire.com/news-releases/aqst-deadline-alert-faruqi--faruqi-llp-reminds-aquestive-therapeutics-aqst-investors-of-securities-class-action-deadline-on-may-4-2026-302749749.html)\n\nSOURCE Faruqi & Faruqi, LLP\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2457438/Faruqi_Logo.jpg\nhttps://mma.prnewswire.com/media/2745617/Faruqi__Faruqi_LLP_James_Josh_Wilson.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-04-22T12:26:00.123887085Z","server_sent_at_ms":1776860760123},"received_at":"2026-04-22T12:26:00.177Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}